Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

118.17 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
43 44 Next >
BAD ETF: The Top “Sin Stock” Holdings in the New Anti-ESG Fund That Debuts Today
There's a new ETF on the block from BAD Investment Company and it seeks to offer investments in sin stocks for interested traders. 
Via InvestorPlace
Expert Ratings For Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following an... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Barclays lifted the price target on FactSet Research Systems Inc. (NYSE: 
Via Benzinga
Analyst Ratings For Biogen
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) withi... 
Via Benzinga
Biogen Slashes Alzheimer's Treatment Price Amid Launch 'Gone Awry'
A maintenance dose of the Alzheimer's drug will cost $28,200 per year. 
Via Investor's Business Daily
Where Biogen Stands With Analysts
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) withi... 
Via Benzinga
Where Biogen Stands With Analysts
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the ... 
Via Benzinga
After Much Criticism, Biogen Slashes Aduhelm Price In Half
In a surprise move, Biogen Inc (NASDAQ: BIIB) announced that it would slash the price of its controversial Alzheimer's drug Aduhelm in half from $56,000 to... 
Via Benzinga
10 Biggest Price Target Changes For Monday
JP Morgan raised the price target on Public Storage (NYSE: 
Via Benzinga
EMA's Committee Gives Thumbs Down To Biogen's Controversial Alzheimer's Drug, As Expected
The European Medicines Agency has recommended the European Commission to reject Biogen Inc's (NASDAQ: BIIB) Aduhelm, an expected blow to its hopes of finding a... 
Via Benzinga
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral... 
Via Benzinga
Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s... 
Via Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
Eli Lilly Pops On Boosted 2021 Outlook As Covid Brings In $2.1 Billion
The U.S. government recently signed a deal for Lilly's Covid antibodies. 
Via Investor's Business Daily
More Specificity is What the Doctor Ordered
Photo by Steven HWG on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner... 
Via Benzinga
Amid Shaky Launch Of Aduhelm, Biogen Mulls Substantial Layoffs: STAT News Report
Between slow sales, safety concerns, and possible European rejection for Alzheimer's disease drug Aduhelm, Biogen Inc (NASDAQ: BIIB) is planning large-scale layoffs... 
Via Benzinga
Omicron Surge
The seemingly good level of joblessness at a mere 184,000 turns out to be less wonderful than it appears, at the lowest since 1969. 
Via Talk Markets
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Early Clinical Data Suggest This New Lotion Could Offer Best-In-Class Eczema Treatment and Infection Prevention, According to Hoth Therapeutics
Image Provided By Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
Should You Blame Biogen for Medicare Part B Premium Hikes?
Yes -- at least partially. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX: 
Via Benzinga
Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone... 
Via Benzinga
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg
Biogen Inc (NASDAQ: BIIB) lost its appeals court bid to revive a key patent on the blockbuster multiple sclerosis drug Tecfidera, reports Bloomberg. In a related ruling... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?
The Swiss pharma needs to get its drug approved first. 
Via The Motley Fool
Exposures Product Safety
2 Moonshot Biotechs with 10x Potential
This strategy identified LGVN stock a month ago, and now its price has skyrocketed. Here are two more biotechs that could do the same. 
Via InvestorPlace
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
43 44 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.